Warning lights
Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.
-
Tight liquidity NBB
Cash and receivables cover 42 % of short-term debt in 2026; threshold 65 %.
-
Not on Peppol Peppol
Not registered in the Peppol network, mandatory for VAT-liable companies since 1 January 2026.
Financials
Financial year 2026
Dr. Charlotte Debergh from Tongeren-Borgloon, company number BE0795660118, closed financial year 2026 with a result of € 123,475 after tax. For that financial year Dr. Charlotte Debergh recorded a gross margin of € 179,667 and equity of € 3,000. Compared with financial year 2025, the result moved from € 126,365 to € 123,475. The company is profitable. The buffer shrank hard: equity is 99 % below last year. High debts against a small own buffer. The most recent annual accounts were filed with the National Bank of Belgium on August 29, 2026.
€ 3,000
▼ 99% vs 2025
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ 123,475
▼ 2% vs 2025
Profit after tax over the fiscal year.
€ 65,917
▼ 73% vs 2025
Cash and bank balances on the last day of the fiscal year.
€ 458,127 paid out
More than the year’s profit went to the shareholders; reserves fell.
People and assets in 2026
≈ 1
No payroll staff. One director, so that person most likely runs the business.
€ 856
▼ 33% vs 2025
No payroll staff. An amount this small is usually a social contribution or pension premium for the director, booked under staff costs.
Debts at end 2026
€ 58,637
▼ 21% vs 2025
€ 15,683 is repaid this year. At this pace the long-term loan is gone in ≈ 4 years.
€ 136
▼ 88% vs 2025
Supplier invoices still open on the last day of the fiscal year.
€ 4,319
▼ 89% vs 2025
Corporate tax and VAT still to pay. No wage debt: nothing outstanding to staff or social security.
Want to see how much further we take a dossier in the Pro version? Open the free De Lijn example and give feedback →
| 2023 | 2024 | 2025 | 2026 | Change 2025 → 2026 | |
|---|---|---|---|---|---|
| Gross margin | € 95,942 | € 175,018 | € 171,762 | € 179,667 | ▲ 5% |
| Profit after taxes | € 75,291 | € 132,997 | € 126,365 | € 123,475 | ▼ 2% |
| Equity | € 78,291 | € 211,288 | € 337,653 | € 3,000 | ▼ 99% |
| Total debts | € 22,518 | € 42,013 | € 112,890 | € 200,606 | ▲ 78% |
| Cash | € 37,485 | € 117,232 | € 244,250 | € 65,917 | ▼ 73% |
| Land & buildings | - | € 1,245 | € 958 | € 671 | ▼ 30% |
| Retained profit | € 75,291 | € 208,288 | € 334,653 | € 0 | ▼ 100% |
| Dividend | € 0 | € 0 | € 0 | € 458,127 | |
| Bank debt | € 0 | € 0 | € 73,819 | € 58,637 | ▼ 21% |
| Balance sheet total | € 100,809 | € 253,301 | € 450,543 | € 203,606 | ▼ 55% |
Key figures of Dr. Charlotte Debergh, fiscal years 2023 to 2026, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2027) expected before 30 January 2028.
What happened to Dr. Charlotte Debergh?
What happened at Dr. Charlotte Debergh in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- New annual accounts for financial year 2026: profit of € 123,475 (▼ 2% vs 2025). Source: NBB ↗
- New establishment in Tongeren-Borgloon. KBO
- Charlotte DEBERGH became a director. NBB
- Start of the company according to the CBE. KBO
In short
From € 75,291 profit in 2023 to € 123,475 profit in 2026.
Paid € 130,432 in corporate taxes since 2023.
Best year ever: 2024, with € 132,997 profit.
Paid out € 458,127 in dividends to the owners in total.
A new publication or filing at Dr. Charlotte Debergh? We notify you, reason included.
Follow Dr. Charlotte DeberghDatabakkes Pro
Know what changes at your customers, suppliers and competitors. Without reading an annual account.
- Follow them in one folder Every company in your folder gets this full dossier: household book, all fiscal years, benchmark against companies of the same size.
- We alert you, with the reason New annual account, Official Gazette publication or status change: you get what changed and where it says so.
- In bulk too, and in ChatGPT and Claude Upload your customer list and get the warning signs back per company. Or ask in your own AI assistant, with this register as the source.
Databakkes Pro is being built. Sign up now and you are first in line for an invitation, with a month to try without a credit card.
De Lijn 8 June 2026 New annual account 2025
filed on 8 June 2026
What was left
€ 20 k ▼ 91%
Money in the bank
€ 178 k ▼ 98%
Open the dossier →
NMBS 8 June 2026 New annual account 2025 What was left ▼ 80%
bpost 18 May 2026 New annual account 2025 What was left from loss to profit
Management
Behind Dr. Charlotte Debergh is Charlotte DEBERGH. It owns 11.1% of Inwendige Ziekten Sint-Trudo itself.
Directors
According to the 2026 annual accounts
Charlotte DEBERGH
Director
since 2023
Establishments
Establishment units
Physical locations of this company
Overhof 9
3840 Tongeren-Borgloon
What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Details
- Company number
- 0795.660.118
- VAT number
- BE 0795.660.118
- Registered office
- Overhof 9, 3840 Tongeren-Borgloon
- Names & denominations
- Dr. Charlotte Debergh
- Enterprise type
- Rechtspersoon
- Legal form
- Private limited company
- Legal situation
- Normale toestand
- Start date
- 3 January 2023
- Peppol
- Not registered